Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:MIRM NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$174.48+0.6%$171.44$111.09▼$183.00$10.67B0.41437,818 shs260,277 shsBBIOBridgeBio Pharma$47.37+0.2%$42.30$21.72▼$48.68$8.99B1.232.19 million shs2.22 million shsMIRMMirum Pharmaceuticals$52.02+0.7%$49.71$36.20▼$54.78$2.58B0.94351,958 shs337,696 shsVRNAVerona Pharma PLC American Depositary Share$105.18+0.1%$94.32$18.51▼$105.50$8.95B0.128.02 million shs3.15 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%+4.19%+0.24%+1.41%+30.70%BBIOBridgeBio Pharma0.00%+2.31%+8.39%+22.82%+82.54%MIRMMirum Pharmaceuticals0.00%+0.37%+4.19%+19.07%+28.29%VRNAVerona Pharma PLC American Depositary Share0.00%-0.11%+15.35%+44.62%+364.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.0705 of 5 stars4.52.00.00.01.91.70.6BBIOBridgeBio Pharma4.7655 of 5 stars4.53.00.03.93.73.30.6MIRMMirum Pharmaceuticals3.7222 of 5 stars3.60.00.04.22.81.70.6VRNAVerona Pharma PLC American Depositary Share2.1626 of 5 stars2.13.00.00.04.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$223.6728.19% UpsideBBIOBridgeBio Pharma 3.00Buy$61.1829.15% UpsideMIRMMirum Pharmaceuticals 3.13Buy$65.5025.91% UpsideVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.003.63% UpsideCurrent Analyst Ratings BreakdownLatest MIRM, ASND, BBIO, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025BBIOBridgeBio PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$56.007/29/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$245.00 ➝ $254.007/29/2025BBIOBridgeBio PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$95.007/21/2025BBIOBridgeBio PharmaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$66.007/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/11/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$213.00 ➝ $243.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.007/10/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M27.11N/AN/A($1.88) per share-92.81BBIOBridgeBio Pharma$221.90M40.53N/AN/A($7.71) per share-6.14MIRMMirum Pharmaceuticals$336.89M7.65N/AN/A$4.70 per share11.07VRNAVerona Pharma PLC American Depositary Share$42.28M211.78N/AN/A$2.56 per share41.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A727.00N/A-93.22%N/A-33.29%8/7/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%8/5/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,506.00N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest MIRM, ASND, BBIO, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42N/AN/AN/A$163.17 millionN/A8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31N/AN/AN/A$107.91 millionN/A8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/A$98.46 millionN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71BBIOBridgeBio PharmaN/A4.574.54MIRMMirum Pharmaceuticals1.323.223.04VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%MIRMMirum PharmaceuticalsN/AVRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma18.20%MIRMMirum Pharmaceuticals14.36%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.15 million36.69 millionOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableMIRMMirum Pharmaceuticals14049.53 million42.42 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableMIRM, ASND, BBIO, and VRNA HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sees Significant Growth in Short InterestAugust 3 at 2:59 AM | americanbankingnews.comShort Interest in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Grows By 6,534.0%August 2 at 3:23 PM | marketbeat.comBrokerages Set Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Target Price at $109.00August 2 at 2:21 AM | americanbankingnews.comBaader Bank Aktiengesellschaft Acquires Shares of 6,870 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 31 at 3:56 AM | marketbeat.comGSA Capital Partners LLP Lowers Stock Holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 31 at 3:55 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Holdings Lessened by TD Asset Management IncJuly 31 at 3:46 AM | marketbeat.comVolatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA StocksJuly 30, 2025 | zacks.comFederated Hermes Inc. Sells 557,532 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 30, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Consensus Rating of "Hold" from AnalystsJuly 30, 2025 | marketbeat.comWedbush Securities Inc. Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 29, 2025 | marketbeat.comMerck’s $10B Verona Deal: A High-Stakes Play in Respiratory CareJuly 29, 2025 | msn.comY Intercept Hong Kong Ltd Takes $721,000 Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 27, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Should You Buy?July 26, 2025 | marketbeat.comNew York State Common Retirement Fund Has $976,000 Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 25, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stake Trimmed by Dorsey Wright & AssociatesJuly 24, 2025 | marketbeat.comBank of New York Mellon Corp Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 24, 2025 | marketbeat.comGW&K Investment Management LLC Sells 38,240 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 23, 2025 | marketbeat.comPathway Capital Management LP Purchases Shares of 98,329 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 21, 2025 | marketbeat.comVerdence Capital Advisors LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 21, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 12-Month High - Here's What HappenedJuly 19, 2025 | marketbeat.comAtle Fund Management AB Acquires New Holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRM, ASND, BBIO, and VRNA Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$174.48 +0.98 (+0.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$173.94 -0.53 (-0.31%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$47.37 +0.10 (+0.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$47.00 -0.37 (-0.78%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Mirum Pharmaceuticals NASDAQ:MIRM$52.02 +0.34 (+0.66%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$52.01 -0.01 (-0.02%) As of 08/1/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$105.18 +0.09 (+0.09%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$105.25 +0.07 (+0.07%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
